Kolexia
Fabbro Michel Oncologie médicale
Fabbro Michel
Oncologie médicale
Icm Montpellier
Montpellier, France
224 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Récidive tumorale locale Carcinomes Glioblastome Tumeurs du cerveau Tumeurs de l'endomètre Tumeurs du sein Gliome

Collaborateurs

Voir plus
Joly Florence
Joly Florence
Hôpital Côte de Nacre, Caen, France
Floquet Anne
Floquet Anne
Institut Bergonié, Bordeaux, France
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France
Berton Dominique
Berton Dominique
Institut de cancérologie de l'Ouest, Saint-Herblain, France

Industries

Voir plus
GSK
9 collaboration(s)
Dernière en 2023
PUBLICLIN
5 collaboration(s)
Dernière en 2022
MSD
4 collaboration(s)
Dernière en 2022
Clovis Oncology
2 collaboration(s)
Dernière en 2021

Dernières activités

Voir plus
Bevacizumab, olaparib, and durvalumab in patients with relapsed ovarian cancer: a phase II clinical trial from the GINECO group.
Nature communications   05 mars 2024
ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in HLA-A2+ Subjects With MAGE-A4 Positive Ovarian Cancer (SURPASS-3): A Phase 2, Open-Label, Randomized, Non-Comparative Clinical Trial of ADP-A2M4CD8 Monotherapy and in Combination With Nivolumab in Subjects With Recurrent Ovarian Cancers
Essai Clinique (Adaptimmune)   15 février 2024
VICTORIA: A Multicentric, Randomized, Non Comparative, Open-label Phase I/II Evaluating AZD2014 (Dual Mammalian Target of Rapamycin Complex 1/2 (mTORC1/mTORC2) Inhibitor) in Combination With Anastrozole Versus Anastrozole Alone in the Treatment of Metastatic Hormone Receptor-positive Endometrial Adenocarcinoma
Essai Clinique (Centre Léon-Bérard)   12 février 2024
StrateGlio: Phase III Randomised Trial Evaluating Treatment Intensification With Temozolomide in Adults With a Glioblastoma
Essai Clinique (Centre Oscar-Lambret)   08 février 2024
HE4 and CA-125 kinetics to predict outcome in patients with recurrent epithelial ovarian carcinoma: the META4 clinical trial.
Frontiers in oncology   11 janvier 2024
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   21 décembre 2023
GYNET: A Randomized, Multicenter, Open Label, Phase I/II Study to Evaluate the Safety, Clinical and Biological Activity of a Humanized Monoclonal Antibody Targeting Netrin-1 (NP137) in Combination With Carboplatin Plus Paclitaxel and/or Pembrolizumab in Patients With Locally Advanced/Metastatic Endometrial Carcinoma or Cervix Carcinoma Progressing/Relapsing After at Least One Prior Systemic Chemotherapy.
Essai Clinique (NETRIS Pharma)   24 novembre 2023
PembroSCCOHT: Multicentric Non-randomized Phase II of Pembrolizumab in Combination With Etoposide-cisplatin-based Chemotherapy in First-line Small Cell Ovarian Carcinoma of Hypercalcemic Type
Essai Clinique (Merck & Co.)   17 novembre 2023
Mixture Model to Predict the Cumulative Incidence of Relapses in Follicular Lymphoma : Need for Longer Follow-up or Alternative Outcomes
65th ASH Annual Meeting Abstracts   02 novembre 2023
Long term activity of vemurafenib in cancers with BRAF mutations: the ACSE basket study for advanced cancers other than BRAF -mutated melanoma.
ESMO open   01 novembre 2023